Fig. 2. Cost effectiveness and sensitivity analysis for PRS-based POAG screening.
Cost-effectiveness acceptability curve for the genetic screening programme in Australia (a) and the UK (b); Tornado diagram demonstrating deterministic one-way sensitivity analysis for Australia (c) and the UK (d) models. The probability that the screening programme is cost-effective at different willingness to pay (WTP) thresholds for Australia (a) and the UK (b) models. The programme was defined as cost-effective if ICER is less than the WTP threshold, which was set at AU$54,808 in Australia and £30,000 in the UK. Costs are given in Australian dollars in c and British pounds in d.